Genmab As Stock Performance

GMAB Stock  USD 33.88  0.78  2.36%   
On a scale of 0 to 100, Genmab AS holds a performance score of 10. The company retains a Market Volatility (i.e., Beta) of 1.24, which attests to a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Genmab AS will likely underperform. Please check Genmab AS's jensen alpha, maximum drawdown, semi variance, as well as the relationship between the sortino ratio and potential upside , to make a quick decision on whether Genmab AS's current trending patterns will revert.

Risk-Adjusted Performance

Fair

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in Genmab AS are ranked lower than 10 (%) of all global equities and portfolios over the last 90 days. Despite somewhat conflicting basic indicators, Genmab AS sustained solid returns over the last few months and may actually be approaching a breakup point. ...more

Actual Historical Performance (%)

One Day Return
2.36
Five Day Return
6.57
Year To Date Return
6.47
Ten Year Return
166.77
All Time Return
798.67
Last Split Factor
5:1
Last Split Date
2018-05-01
1
Genmab AS Q3 2025 Earnings Call Transcript
11/11/2025
2
Transactions With Shares and Linked Securities in Genmab AS Made by Managerial Employees and Their Closely Associated Persons
12/01/2025
3
AS Genmab Purchases 120,752 Shares of Merus Stock
12/19/2025
4
Genmab AS Shares Gap Up - Still a Buy - MarketBeat
12/24/2025
5
Genmab ends development of late-stage oncology asset acasunlimab
12/29/2025
6
Heres Why Genmab AS Rose in Q3
12/31/2025
7
Genmab to Present at the 44th Annual J.P. Morgan Healthcare Conference
01/05/2026
8
Genmab AS Reaches New 1-Year High Heres What Happened
01/07/2026
9
Genmab AS A Bull Case Theory
01/15/2026
10
Genmab AS Shares Gain Analyst Support as Deutsche Bank Sees Oncology Upside
01/20/2026
11
Genmab s Future Potential Underappreciated by Market
01/22/2026
12
CD137 Targeted Therapy Research Report 2026-2030 90 Therapies in Clinical Trials, Upcoming Commercial Launches, Global Regional Clinical Commercial Trends,
01/23/2026
Begin Period Cash Flow14.9 B
Total Cashflows From Investing Activities-9.9 B

Genmab AS Relative Risk vs. Return Landscape

If you would invest  2,913  in Genmab AS on October 28, 2025 and sell it today you would earn a total of  475.00  from holding Genmab AS or generate 16.31% return on investment over 90 days. Genmab AS is currently generating 0.265% in daily expected returns and assumes 2.0715% risk (volatility on return distribution) over the 90 days horizon. In different words, 18% of stocks are less volatile than Genmab, and 95% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon.
  Expected Return   
       Risk  
Given the investment horizon of 90 days Genmab AS is expected to generate 2.81 times more return on investment than the market. However, the company is 2.81 times more volatile than its market benchmark. It trades about 0.13 of its potential returns per unit of risk. The Dow Jones Industrial is currently generating roughly 0.07 per unit of risk.

Genmab AS Target Price Odds to finish over Current Price

The tendency of Genmab Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to move above the current price in 90 days
 33.88 90 days 33.88 
about 6.68
Based on a normal probability distribution, the odds of Genmab AS to move above the current price in 90 days from now is about 6.68 (This Genmab AS probability density function shows the probability of Genmab Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days the stock has the beta coefficient of 1.24 . This usually indicates as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Genmab AS will likely underperform. Additionally Genmab AS has an alpha of 0.0832, implying that it can generate a 0.0832 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta).
   Genmab AS Price Density   
       Price  

Predictive Modules for Genmab AS

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Genmab AS. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Hype
Prediction
LowEstimatedHigh
31.6433.7135.78
Details
Intrinsic
Valuation
LowRealHigh
33.4135.4837.55
Details
Naive
Forecast
LowNextHigh
31.0333.1035.17
Details
9 Analysts
Consensus
LowTargetHigh
34.6438.0742.26
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Genmab AS. Your research has to be compared to or analyzed against Genmab AS's peers to derive any actionable benefits. When done correctly, Genmab AS's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in Genmab AS.

Genmab AS Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. Genmab AS is not an exception. The market had few large corrections towards the Genmab AS's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Genmab AS, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Genmab AS within the framework of very fundamental risk indicators.
α
Alpha over Dow Jones
0.08
β
Beta against Dow Jones1.24
σ
Overall volatility
1.68
Ir
Information ratio 0.05

Genmab AS Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Genmab AS for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Genmab AS can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
Genmab AS is unlikely to experience financial distress in the next 2 years
Genmab AS has a strong financial position based on the latest SEC filings
Latest headline from finance.yahoo.com: CD137 Targeted Therapy Research Report 2026-2030 90 Therapies in Clinical Trials, Upcoming Commercial Launches, Global Regional Clinical Commercial Trends,

Genmab AS Price Density Drivers

Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Genmab Stock often depends not only on the future outlook of the current and potential Genmab AS's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Genmab AS's indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding646.3 M
Cash And Short Term Investments21.1 B

Genmab AS Fundamentals Growth

Genmab Stock prices reflect investors' perceptions of the future prospects and financial health of Genmab AS, and Genmab AS fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Genmab Stock performance.

About Genmab AS Performance

By analyzing Genmab AS's fundamental ratios, stakeholders can gain valuable insights into Genmab AS's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Genmab AS has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Genmab AS has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Last ReportedProjected for Next Year
Days Of Inventory On Hand 26.42  25.10 
Return On Tangible Assets 0.23  0.24 
Return On Capital Employed 0.15  0.16 
Return On Assets 0.15  0.16 
Return On Equity 0.19  0.20 

Things to note about Genmab AS performance evaluation

Checking the ongoing alerts about Genmab AS for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Genmab AS help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Genmab AS is unlikely to experience financial distress in the next 2 years
Genmab AS has a strong financial position based on the latest SEC filings
Latest headline from finance.yahoo.com: CD137 Targeted Therapy Research Report 2026-2030 90 Therapies in Clinical Trials, Upcoming Commercial Launches, Global Regional Clinical Commercial Trends,
Evaluating Genmab AS's performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate Genmab AS's stock performance include:
  • Analyzing Genmab AS's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
  • Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Genmab AS's stock is overvalued or undervalued compared to its peers.
  • Examining Genmab AS's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
  • Evaluating Genmab AS's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Genmab AS's management team can help you assess the Company's leadership.
  • Pay attention to analyst opinions and ratings of Genmab AS's stock. These opinions can provide insight into Genmab AS's potential for growth and whether the stock is currently undervalued or overvalued.
It's essential to remember that evaluating Genmab AS's stock performance is not an exact science, and many factors can impact Genmab AS's stock market price. Therefore, it's also important to diversify your portfolio and not rely solely on one company or stock for your investments.

Complementary Tools for Genmab Stock analysis

When running Genmab AS's price analysis, check to measure Genmab AS's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Genmab AS is operating at the current time. Most of Genmab AS's value examination focuses on studying past and present price action to predict the probability of Genmab AS's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Genmab AS's price. Additionally, you may evaluate how the addition of Genmab AS to your portfolios can decrease your overall portfolio volatility.
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
AI Portfolio Prophet
Use AI to generate optimal portfolios and find profitable investment opportunities
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments